Furthermore, trials of administration of ghrelin or its receptor agonist in human clinical trials and animal studies show favorable results improving the symptoms of gastroparesis, supporting the theory of its dysregulation in the pathophysiology of GNDs [52]. The gene discussed is GHRL; the disease is gastroparesis.